Exploring Novel Approaches To Eliminate Hiv Reservoirs To Achieve A Cure For Hiv

This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

HIV/AIDS continues to be one of the most challenging individual and public health concerns of the present day. According to the UNAIDS, nearly 38 million individuals were living with the infection by the end of 2018, while 1.7 million new cases occurred during that same year. In spite of the numerous advances in the development and delivery of antiretroviral agents, both for treatment and prevention, several challenges remain. This book includes original research and review articles on innovative strategies and approaches for the formulation and delivery of anti-HIV drugs, including genetic material and other biopharmaceuticals. Different local and systemic delivery strategies are addressed based on different technologies intended for oral, transdermal, subcutaneous, vaginal, or rectal administration. Authored by eminent scientists in academia and nonprofit organizations involved in the development of antiretroviral drug products, this collection provides useful information for all those involved in HIV/AIDS treatment and prevention.

These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care. This edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.

Paralleling the discovery of HIV and the rise of the AIDS pandemic, a flock of naysayers has dedicated itself to replacing genuine knowledge with destructive misinformation—and spreading from the fringe to the mainstream media and the think tank. Now from the editor of the journal AIDS and Behavior comes a bold exposé of the scientific and sociopolitical forces involved in this toxic evasion. Denying AIDS traces the origins of AIDS dissidents disclaimers during the earliest days of the epidemic and delves into the psychology and politics of the current denial movement in its various incarnations. Seth Kalichman focuses not on the “difficult” or doubting patient, but on organized, widespread forms of denial (including the idea that HIV itself is a myth and HIV treatments are poison) and the junk science, faulty logic, conspiracy theories, and larger forces of homophobia and racism that fuel them. The malignant results of AIDS denial can be seen in those individuals who refuse to be tested, ignore their diagnoses, or reject the treatments that could save their lives. Instead of ignoring these currents, asserts Kalichman, science has a duty to counter them. Among the topics covered: Why AIDS denialism endures, and why science must understand it. Pioneer virus HIV researcher Peter Duesberg’s role in AIDS denialism. Flawed immunological, virological, and pharmacological pseudoscience studies that are central to texts of denialism. The social conservative agenda and the politics of AIDS denial, from the courts to the White House. The impact of HIV misinformation on public health in South Africa. Fighting fiction with reality: anti-denialism and the scientific community. For anyone affected by, interested in, or working with researchers in HIV/AIDS, and public health professionals in general, the insight and vision of Denying AIDS will inspire outrage, discussion, and ultimately action. See http://denyingaids.blogspot.com/ for more information.